Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized Trial

被引:23
作者
Ray, Michael E. [1 ]
Bae, Kyounghwa [2 ]
Hussain, Maha H. A. [3 ]
Hanks, Gerald E. [5 ]
Shipley, William U. [6 ]
Sandler, Howard M. [4 ]
机构
[1] Radiol Associates Appleton, Appleton, WI 54911 USA
[2] Radiat Therapy Oncol Grp, Dept Stat, Philadelphia, PA USA
[3] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[5] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[6] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
关键词
THERAPY ONCOLOGY GROUP; GROUP PROTOCOL 92-02; RADIATION-THERAPY; RADICAL PROSTATECTOMY; ANDROGEN DEPRIVATION; BIOCHEMICAL FAILURE; ADJUVANT THERAPY; COLON-CANCER; RADIOTHERAPY; CARCINOMA;
D O I
10.1093/jnci/djn489
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The identification of surrogate endpoints for prostate cancer-specific survival may shorten the length of clinical trials for prostate cancer. We evaluated distant metastasis and general clinical treatment failure as potential surrogates for prostate cancer-specific survival by use of data from the Radiation Therapy and Oncology Group 92-02 randomized trial. Methods Patients (n = 1554 randomly assigned and 1521 evaluable for this analysis) with locally advanced prostate cancer had been treated with 4 months of neoadjuvant and concurrent androgen deprivation therapy with external beam radiation therapy and then randomly assigned to no additional therapy (control arm) or 24 additional months of androgen deprivation therapy (experimental arm). Data from landmark analyses at 3 and 5 years for general clinical treatment failure (defined as documented local disease progression, regional or distant metastasis, initiation of androgen deprivation therapy, or a prostate-specific antigen level of 25 ng/mL or higher after radiation therapy) and/or distant metastasis were tested as surrogate endpoints for prostate cancer-specific survival at 10 years by use of Prentice's four criteria. All statistical tests were two-sided. Results At 3 years, 1364 patients were alive and contributed data for analysis. Both distant metastasis and general clinical treatment failure at 3 years were consistent with all four of Prentice's criteria for being surrogate endpoints for prostate cancer-specific survival at 10 years. At 5 years, 1178 patients were alive and contributed data for analysis. Although prostate cancer-specific survival was not statistically significantly different between treatment arms at 5 years (P=.08), both endpoints were consistent with Prentice's remaining criteria. Conclusions Distant metastasis and general clinical treatment failure at 3 years may be candidate surrogate endpoints for prostate cancer-specific survival at 10 years. These endpoints, however, must be validated in other datasets. J Natl Cancer Inst 2009; 101: 228-236
引用
收藏
页码:228 / 236
页数:9
相关论文
共 50 条
[41]   The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024 [J].
Miszczyk, Marcin ;
Rajwa, Pawel ;
Fazekas, Tamas ;
Briganti, Alberto ;
Karakiewicz, Pierre I. ;
Roupret, Morgan ;
Shariat, Shahrokh F. .
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (06) :1195-1198
[42]   Sexual Function After Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: Results From the Randomized Phase III HYPRO Trial [J].
Wortel, Ruud C. ;
Pos, Floris J. ;
Heemsbergen, Wilma D. ;
Incrocci, Luca .
Journal of Sexual Medicine, 2016, 13 (11) :1695-1703
[43]   Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial [J].
Niazi, Tamim ;
Kaldany, Edmond ;
Tisseverasinghe, Steven ;
Malagon, Talia ;
Bahoric, Boris ;
McPherson, Victor ;
Rompre-Brodeur, Alexis ;
Anidjar, Maurice .
CANCERS, 2023, 15 (13)
[44]   Testing radical prostatectomy in men with prostate cancer and oligometastases to the bone: a randomized controlled feasibility trial [J].
Sooriakumaran, Prasanna .
BJU INTERNATIONAL, 2017, 120 (5B) :E8-E20
[45]   Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials [J].
D'Amico, Anthony V. ;
Chen, Ming-Hui ;
de Castro, Mario ;
Loffredo, Marian ;
Lamb, David S. ;
Steigler, Allison ;
Kantoff, Philip W. ;
Denham, James W. .
LANCET ONCOLOGY, 2012, 13 (02) :189-195
[46]   Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints [J].
Meier, Robert M. ;
Bloch, Daniel A. ;
Cotrutz, Cristian ;
Beckman, Alan C. ;
Henning, George T. ;
Woodhouse, Shermian A. ;
Williamson, Shirnett K. ;
Mohideen, Najeeb ;
Dombrowski, John J. ;
Hong, Robert L. ;
Brachman, David G. ;
Linson, Patrick W. ;
Kaplan, Irving D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (02) :296-303
[47]   Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer [J].
Ishiguro, Megumi ;
Mochizuki, Hidetaka ;
Tomita, Naohiro ;
Shimada, Yasuhiro ;
Takahashi, Keiichi ;
Kotake, Kenjiro ;
Watanabe, Masahiko ;
Kanemitsu, Yukihide ;
Ueno, Hideki ;
Ishikawa, Toshiaki ;
Uetake, Hiroyuki ;
Matsui, Shigeyuki ;
Teramukai, Satoshi ;
Sugihara, Kenichi .
BMC CANCER, 2012, 12
[48]   Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials [J].
Esteva, Andre ;
Feng, Jean ;
van der Wal, Douwe ;
Huang, Shih-Cheng ;
Simko, Jeffry P. ;
DeVries, Sandy ;
Chen, Emmalyn ;
Schaeffer, Edward M. ;
Morgan, Todd M. ;
Sun, Yilun ;
Ghorbani, Amirata ;
Naik, Nikhil ;
Nathawani, Dhruv ;
Socher, Richard ;
Michalski, Jeff M. ;
Roach, Mack, III ;
Pisansky, Thomas M. ;
Monson, Jedidiah M. ;
Naz, Farah ;
Wallace, James ;
Ferguson, Michelle J. ;
Bahary, Jean-Paul ;
Zou, James ;
Lungren, Matthew ;
Yeung, Serena ;
Ross, Ashley E. ;
Sandler, Howard M. ;
Tran, Phuoc T. ;
Spratt, Daniel E. ;
Pugh, Stephanie ;
Feng, Felix Y. ;
Mohamad, Osama .
NPJ DIGITAL MEDICINE, 2022, 5 (01)
[49]   Impact of local treatment on overall survival of patients with metastatic prostate cancer: systematic review and meta-analysis [J].
Carneiro, Arie ;
Baccaglini, Willy ;
Glina, Felipe P. A. ;
Kayano, Paulo P. ;
Nunes, Victor M. ;
Smaletz, Oren ;
Bernardo, Wanderley Marques ;
de Carvalho, Icaro Thiago ;
Lemos, Gustavo Caserta .
INTERNATIONAL BRAZ J UROL, 2017, 43 (04) :588-599
[50]   Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Lin, Deng-Yn ;
Park, Joong-Won ;
Kudo, Masatoshi ;
Qin, Shukui ;
Chung, Hyun-Cheol ;
Song, Xiangqun ;
Xu, Jianming ;
Poggi, Guido ;
Omata, Masao ;
Lowenthal, Susan Pitman ;
Lanzalone, Silvana ;
Yang, Liqiang ;
Lechuga, Maria Jose ;
Raymond, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (32) :4067-+